Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Discovery Chemistry Congress

Ben Davis's Biography



Ben Davis, Research Fellow, Vernalis Ltd

Ben Davis studied protein structure and folding for his PhD with Professor Alan Fersht at Cambridge University, before moving to Dr Paul Driscoll’s group at University College London where he studied protein-ligand interactions by NMR. In 1998 he joined RiboTargets, a biotech company formed out of the Laboratory of Molecular Biology in Cambridge,where he worked on applying structure based drug discovery techniques to a variety of RNA and protein targets. In 2003 RiboTargets became Vernalis R&D, and concentrated research on protein targets. Since 2001, he has been focussed on the development of the fragment based lead discovery (FBLD) technology, and the application of FBLD methods to a wide range of therapeutic targets. Vernalis currently has a number of compounds derived from FBLD in Phase I and II clinical trials.

Ben Davis Image

Roundtable Discussion - What are the Issues and Challenges in Applying FBLD to a Drug Discovery Program?

Tuesday, 18 February 2014 at 18:00

Add to Calendar ▼2014-02-18 18:00:002014-02-18 19:00:00Europe/LondonRoundtable Discussion - What are the Issues and Challenges in Applying FBLD to a Drug Discovery Program?Discovery Chemistry Congress in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com

Key areas for discussion:
- How big should an FBLD library be, and what chemical matter should it contain?
- What’s the best way to screen for fragments? Does it make a difference what technique is used?
- How can we best integrate FBLD hits with hits from other drug discovery approaches?
- Is a crystal structure required for a successful FBLD campaign?

The discussions will be held in the Exhibition Hall.


Add to Calendar ▼2014-02-18 00:00:002014-02-19 00:00:00Europe/LondonDiscovery Chemistry CongressDiscovery Chemistry Congress in Barcelona, SpainBarcelona, SpainSELECTBIOenquiries@selectbiosciences.com